New combo attack on recurrent rectal cancer shows promise in early trial
NCT ID NCT07183865
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial is testing a powerful mix of radiation, chemotherapy, immunotherapy, and targeted therapy in 44 patients with locally recurrent rectal cancer that has not responded to prior treatment. The goal is to shrink tumors and enable surgery. Researchers are measuring how many patients see their tumors shrink or disappear, and how long that effect lasts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY RECURRENT RECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, 200032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Irinotecan hydrochloride liposome, 5-FU, leucovorin, PD-1 antibody (SG001), and targeted therapy (C225 or bevacizumab)
What this could lead to
If successful, this could offer a new treatment option for patients with recurrent rectal cancer that has not responded to standard chemotherapy, potentially improving tumor shrinkage and surgical outcomes.
What could go wrong
This is an early-phase, single-arm trial with only 44 participants, so results may not apply to all patients. The combination therapy has multiple drugs, increasing the risk of side effects, and it is not yet compared to standard treatments.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.